Zobrazeno 1 - 10
of 18
pro vyhledávání: '"James, Trammel"'
Autor:
Christine Juergens, James Trammel, Yasuko Shoji, Scott Patterson, Wendy Watson, Chris Webber, William C. Gruber, Daniel A. Scott, Beate Schmoele-Thoma
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 14, Iss 8, Pp 1948-1956 (2018)
Injection site reactions (ISRs; redness, swelling and pain) commonly occur within 1–2 days after vaccination. After administration of toxoid vaccines including diphtheria toxoid, a later onset of ISRs has also been observed. As the serotype capsula
Externí odkaz:
https://doaj.org/article/2d2e4e785345446ba9adade0dd1bf60c
Autor:
Allison Thompson, Nicola P. Klein, James Trammel, Shelly Senders, Wendy Watson, Erik Lamberth, Daniel A. Scott, Kathrin U. Jansen, Yahong Peng, William C. Gruber, Jelena Drozd, Peter C. Giardina
Publikováno v:
The Pediatric Infectious Disease Journal
Supplemental Digital Content is available in the text.
Background: The development and widespread use of pneumococcal conjugate vaccines (PCVs) substantially reduced the global burden of pneumococcal disease. Expanding the serotypes covered by P
Background: The development and widespread use of pneumococcal conjugate vaccines (PCVs) substantially reduced the global burden of pneumococcal disease. Expanding the serotypes covered by P
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Background Pneumococcal conjugate vaccines (PCVs) elicit lower immune response against serotypes carried before or at the time of vaccination (hyporesponsiveness) in infants. The limited studies conducted to date did not permit comprehensive insights
Autor:
David Greenberg, Ron Dagan, James Trammel, Noga Givon-Lavi, William C. Gruber, Scott Patterson, Christine Juergens, Daniel A. Scott, Nurith Porat
Publikováno v:
Vaccine. 35:945-950
Background In addition to reducing vaccine-type nasopharyngeal carriage rates, pneumococcal conjugate vaccines (PCVs) may decrease carriage density in vaccinated individuals still carrying vaccine serotypes. However, reduction of carriage density has
Autor:
Allison Thompson, Jelena Drozd, Yahong Peng, Kathrin U. Jansen, Peter C. Giardina, Wendy Watson, Shelly Senders, Nicola P. Klein, William C. Gruber, Erik Lamberth, Daniel A. Scott, James Trammel
Publikováno v:
Open Forum Infectious Diseases
Background A 20-valent pneumococcal conjugate vaccine (PCV20) is being developed to extend protection against pneumococcal disease beyond that of the 13-valent pneumococcal vaccine (PCV13). This is the first safety and immunogenicity study of PCV20 i
Autor:
Yasuko Shoji, Chris Webber, Beate Schmoele-Thoma, William C. Gruber, Scott Patterson, James Trammel, Wendy Watson, Christine Juergens, Daniel A. Scott
Publikováno v:
Human vaccinesimmunotherapeutics. 14(8)
Injection site reactions (ISRs; redness, swelling and pain) commonly occur within 1-2 days after vaccination. After administration of toxoid vaccines including diphtheria toxoid, a later onset of ISRs has also been observed. As the serotype capsular
Autor:
Michael Pichichero, Ravinder Kaur, Daniel A Scott, William C Gruber, James Trammel, Anthony Almudevar, Kimberly J Center
Publikováno v:
The Lancet. Childadolescent health. 2(8)
Summary Background With wide use of the seven-valent pneumococcal conjugate vaccine (PCV7) for protection against acute otitis media caused by Streptococcus pneumoniae serotypes included in the vaccine, efficacy testing for the 13-valent vaccine (PCV
Autor:
Scott Patterson, Marc Lipsitch, William C. Gruber, Ron Dagan, Christine Juergens, Lucy M Li, Daniel A. Scott, James Trammel
Background The magnitude of an individual’s serotype-specific immunoglobulin G (IgG) response to a pneumococcal conjugate vaccine (PCV) has been associated with the vaccine’s protective efficacy against carriage of pneumococci of that serotype, t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e25fef337d49a5bef1279a15037cb3aa
https://europepmc.org/articles/PMC5767551/
https://europepmc.org/articles/PMC5767551/
Autor:
David Greenberg, Noga Givon-Lavi, Alejandra Gurtman, James Trammel, Ron Dagan, Christine Juergens, Daniel A. Scott, Scott Patterson, David A. Cooper, William C. Gruber
Publikováno v:
Clinical and Vaccine Immunology. 21:1277-1281
In a randomized double-blind trial in healthy Israeli infants in Israel who received the 13-valent or 7-valent pneumococcal conjugate vaccine (PCV13 or PCV7, respectively) at 2, 4, 6, and 12 months, PCV13 significantly reduced nasopharyngeal (NP) col
Autor:
Takehiro, Togashi, Masako, Yamaji, Allison, Thompson, Peter C, Giardina, Masakazu, Aizawa, Scott, Patterson, William C, Gruber, Daniel A, Scott, James, Trammel
Publikováno v:
Pediatric Infectious Disease Journal. 32:984-989
A 13-valent pneumococcal conjugate vaccine (PCV13) containing 6 additional serotypes not included in the 7-valent PCV has been developed to broaden protection against Streptococcus pneumoniae, which is responsible for over 500,000 deaths annually wor